Processa Pharmaceuticals
PCSA
10 hedge funds and large institutions have $448K invested in Processa Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 3 closing their positions.
35% more capital invested
Capital invested by funds: $331K → $448K (+$117K)
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
1.6% more ownership
Funds ownership: 5.08% → 6.68% (+1.6%)
0% more funds holding
Funds holding: 10 → 10 (0)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Connective Capital Management
Palo Alto,
California
|
+$193K |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$117K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$26.2K |
| 4 |
Citigroup
New York
|
+$38 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$86.9K |
| 2 |
HF
HRT Financial
New York
|
-$56K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$27.6K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.29K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$52 |
PCSA Hedge Fund Activity: Q1 2026 in Review
10 of the 8,206 institutional investors tracked by Wall St. Rank reported a position in Processa Pharmaceuticals (PCSA) for Q1 2026, worth a combined $448K — up 35% from $331K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new PCSA positions and 3 closed out — a net gain of 1 holder — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Connective Capital Management, opening a new position worth an estimated $193K. The largest seller was Jane Street, exiting entirely with an estimated $86.9K sold.
- 10 institutional investors held Processa Pharmaceuticals (PCSA) as of Q1 2026, unchanged from Q4 2025.
- Funds reported $448K of Processa Pharmaceuticals stock for Q1 2026, up 35% quarter-over-quarter.
- 4 funds opened new Processa Pharmaceuticals positions in Q1 2026 and 3 closed out, a net change of +1 holder.
- The largest Processa Pharmaceuticals buyer in Q1 2026 was Connective Capital Management, an estimated $193K added.
- The largest Processa Pharmaceuticals seller in Q1 2026 was Jane Street, an estimated $86.9K sold.
Based on aggregated 13F filings for Q1 2026.